Welcome to our dedicated page for Senti Biosciences Holdings SEC filings (Ticker: SNTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Senti Biosciences SEC filings document a clinical-stage biotechnology issuer built around the Gene Circuit platform and its cell-therapy pipeline. The company’s 8-K reports cover operating and financial results, corporate updates, clinical or regulatory disclosures, shareholder voting matters, governance items, capital-structure matters and material agreements, including research-and-development laboratory lease disclosures.
The filing record also includes a Form 15-12G for Senti Biosciences, Inc. after a completed Delaware holding company reorganization under which Senti became a subsidiary within Senti Biosciences Holdings. That filing addresses termination or suspension of Exchange Act registration and reporting duties for the covered Senti common stock, alongside the issuer’s corporate-status and security-class disclosures.
Senti Biosciences Holdings, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add the Part III sections on directors, executive compensation, security ownership and related-party matters. The amendment does not change previously filed financial statements.
The filing details the board’s classified structure, committee memberships and independence determinations, as well as the non-employee director cash retainers and stock option program. It also summarizes 2025 pay for key executives, including salary, equity awards and potential severance on termination or change of control, and discloses equity plan capacity and major shareholders, with 31,144,754 common shares outstanding as of March 27, 2026.
Senti Biosciences Holdings, Inc. filed a Post-Effective Amendment No. 1 to its Form S-3 to reflect a holding company reorganization completed on April 24, 2026. The Successor Registrant expressly adopts the existing Registration Statement (No. 333-285985) under Rule 414. No additional securities are being registered by this Amendment. The filing describes the Merger Agreement effectuating the reorganization, confirms a one-for-one conversion of Predecessor common shares into Successor common shares, and incorporates the Successor’s amended certificate of incorporation and bylaws. The document also recites indemnification provisions, advancement of expenses, and indemnification agreements for officers and directors.
Senti Biosciences Holdings, Inc. filed a Post-Effective Amendment No. 1 to its Form S-3 on April 24, 2026 reflecting a holding company reorganization completed the same day. The amendment states that each outstanding share of the predecessor's common stock was converted into one share of the successor's common stock, and no additional securities are being registered by this amendment. The successor adopted organizational documents substantially identical to the predecessor's and expressly adopts the Registration Statement (File No. 333-285983) pursuant to Rule 414.
Senti Biosciences Holdings, Inc. filed Post-Effective Amendment No. 2 to its registration statement (Registration No. 333-265873) to reflect a holding company reorganization completed on April 24, 2026. The amendment states that 2,000,000 Earn-Out Shares originally registered are no longer issuable and have been removed from registration. The Successor Registrant adopted organizational documents substantially identical to the Predecessor and expressly adopts the prior registration statement under Rule 414. No additional securities are being registered pursuant to this amendment.
Senti Biosciences, Inc. files Post-Effective Amendment No. 2 to remove from registration the resale of 8,727,049 shares of its common stock previously registered for resale by Chardan Capital Markets LLC.
The amendment states the Registrant is no longer required to register the resale under the Registration Rights Agreement and has terminated the related offering.
Bayer HealthCare LLC and affiliated reporting persons filed an amended Schedule 13D showing a significant ownership position in Senti Biosciences, Inc. They report beneficial ownership of 6,142,848 shares of common stock, representing 17.82% of the company.
This total includes 3,333,000 shares underlying a warrant for Senti common stock that is exercisable in full within 60 days of the filing date. The ownership percentage is based on 31,144,497 Senti common shares outstanding as of March 19, 2026, as reported in the company’s Form 10-K.
Senti Biosciences, Inc. plans a tax-free holding company reorganization, targeted to become effective by April 16, 2026. The company would merge into a new subsidiary, with Senti Biosciences Holdings, Inc. becoming the successor issuer.
Each existing share of Senti common stock would automatically convert into an equivalent share of Senti Biosciences Holdings common stock with the same rights. Shares would continue trading on the Nasdaq Capital Market under the symbol SNTI with a new CUSIP number, and stockholders are expected not to recognize gain or loss for U.S. federal income tax purposes. Directors, officers, assets, businesses and operations would remain the same after the reorganization, though the company may decide not to complete it or could delay completion.
New Enterprise Associates 15, L.P. and affiliated entities report an updated ownership position in Senti Biosciences, Inc. They beneficially own 3,775,615 shares of Senti’s common stock, representing 12.1% of the outstanding shares based on 31,144,497 shares outstanding as of March 19, 2026. The filing states that this Amendment No. 3 is being made because their percentage ownership decreased by more than 1% due to an increase in Senti’s shares outstanding, not because of recent share sales or purchases. NEA 15 acquired the shares for investment purposes and may buy or sell additional shares in the future depending on market conditions and its evaluation of the company, but it currently has no specific plans for corporate actions such as mergers, board changes, or major asset sales.
Senti Biosciences, Inc. is a clinical-stage biotech company developing gene circuit–enabled cell and gene therapies, with a primary focus on oncology. Its lead program, SENTI-202, is an off-the-shelf CAR-NK cell therapy for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML).
In a Phase 1 trial, SENTI-202 showed a 50% overall response rate in twenty AML patients, with 42% achieving complete remission or CRh and most remissions being MRD-negative at the recommended Phase 2 dose. The FDA granted SENTI-202 Orphan Drug and RMAT designations, reflecting its potential in a high‑need setting.
The company is expanding its pipeline using a modular gene circuit platform (Logic Gating, Multi-Arming, Regulator Dials, Smart Sensors) across NK, T cells, and gene therapy modalities, and maintains collaborations with partners such as BlueRock Therapeutics and Celest Therapeutics, plus multiple NCI license agreements. As of March 19, 2026, Senti had 31,144,497 common shares outstanding and a non‑affiliate market value of approximately $53.2 million as of June 30, 2025.